Xolair (omalizumab, J2357) Reimbursement — ASP & Payment Limit Trend

What this means for buy-and-bill margin

At the Q3 2026 limit of $46.588 per 5 mg, the implied ASP is about $43.951 and the on-paper add-on is $2.637 per 5 mg. After the 2% sequester on Medicare’s 80% share, the effective add-on is roughly 4.3% of ASP — about $1.89 per 5 mgwhen the full allowable is collected. Whether that covers your carrying cost, waste, and denials depends on your acquisition price against ASP — which is exactly the number the payment limit can’t see, and the comparison the practice X-Ray runs with your actuals.

Billing essentials: dose → units → dollars

Dose math. CSU: a flat 300 mg SC every 4 weeks — not IgE- or weight-based — = 60 billing units (5 mg/unit); asthma dosing is IgE/weight-tiered at 75–375 mg q2/4w. At the Q3 2026 limit of $46.588 per 5 mg, a typical 60-unit dose carries a Medicare allowable of about $2,795.28 — Medicare pays ~$2,191.50 after the sequester, and ~$559.056 rides on coinsurance collection. Part B spent $419.8 million on J2357 in 2023 across 17,787 beneficiaries (CMS Part B drug-spending data).

Administration. 96372 per injection — the label requires healthcare-setting initiation with post-dose anaphylaxis observation (boxed warning); self-administration only after three tolerated doses.

Waste modifiers. Single-dose container — JW (documented discard) / JZ (no waste) modifiers required since July 2023. Run your own numbers on the buy-and-bill calculator.

The coding & patient-cost side. For billing references across 370+ drugs (dosing conversions, modifiers, payer policies, patient cost), see CareCost Estimate’s drug library, our billing-reference sister site.

Sourcing & payer-control status

Where J2357stands in the national payers’ published sourcing programs (the office-vs-hospital setting distinction most coverage misses):

• On UnitedHealthcare's medication-sourcing list (May 2026 chart, PCA-1-26-00902).
• On Aetna's CBM pharmacy-benefit migration list (April 2026 documents) — fully-insured plans, outside the 12 carve-out states; also under Aetna's site-of-care precertification policy.
• On Cigna's Pathwell Specialty list (Jan 2026) — and named a preferred alternative for Cinqair.

State law is the other half: the white-bagging laws-by-state tracker — 11 states currently ban payer sourcing mandates outright.

FAQ

Which limits moved this quarter, across all drugs: the ASP-change leaderboard. How this data is built and verified: the Data Desk. Billing reference (dosing, modifiers, admin CPTs): CareCost Estimate’s drug library.